title: Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer.
abstract: BACKGROUND
  Aggressive treatment of peritoneal metastases from colon cancer by surgical cytoreduction and infusional intraperitoneal (IP) chemotherapy may benefit selected patients. We reviewed our institutional experience to assess patient selection, complications, and outcome.
  
  
  METHODS
  Patients having surgical debulking and IP 5-fluoro-2'-deoxyuridine (FUDR) plus leucovorin (LV) for peritoneal metastases from 1987 to 1999 were evaluated retrospectively.
  
  
  RESULTS
  There were 64 patients with a mean age of 50 years. Primary tumor sites were 47 in the colon and 17 in the appendix. Peritoneal metastases were synchronous in 48 patients and metachronous in 16 patients. Patients received IP FUDR (1000 mg/m2 daily for 3 days) and IP leucovorin (240 mg/m2) with a median cycle number of 4 (range, 1-28). The median number of complications was 1 (range, 0-5), with no treatment related mortality. Only six patients (9%) required termination of IP chemotherapy because of complications. The median follow-up was 17 months (range, 0-132 months). The median survival was 34 months (range, 2-132); 5-year survival was 28%. Lymph node status, tumor grade, and interval to peritoneal metastasis were not statistically significant prognostic factors for survival. Complete tumor resection was significant on multivariate analysis (P = .04), with a 5-year survival of 54% for complete (n = 19) and 16% for incomplete (n = 45) resection.
  
  
  CONCLUSIONS
  Surgical debulking and IP FUDR for peritoneal metastases from colon cancer can be accomplished safely and has yielded an overall 5-year survival of 28%. Complete resection is associated with improved survival (54% at 5 years) and is the most important prognostic indicator.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
authors.forename: A T
authors.initials: AT
authors.lastname: Culliford
authors.forename: A D
authors.initials: AD
authors.lastname: Brooks
authors.forename: S
authors.initials: S
authors.lastname: Sharma
authors.forename: L B
authors.initials: LB
authors.lastname: Saltz
authors.forename: G K
authors.initials: GK
authors.lastname: Schwartz
authors.forename: E M
authors.initials: EM
authors.lastname: O'Reilly
authors.forename: D H
authors.initials: DH
authors.lastname: Ilson
authors.forename: N E
authors.initials: NE
authors.lastname: Kemeny
authors.forename: D P
authors.initials: DP
authors.lastname: Kelsen
authors.forename: J G
authors.initials: JG
authors.lastname: Guillem
authors.forename: W D
authors.initials: WD
authors.lastname: Wong
authors.forename: A M
authors.initials: AM
authors.lastname: Cohen
authors.forename: P B
authors.initials: PB
authors.lastname: Paty
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001063:Appendiceal Neoplasms; D003110:Colonic Neoplasms; D003131:Combined Modality Therapy; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use; D005575:Formyltetrahydrofolates / Q000627:therapeutic use; D006801:Humans; D007263:Infusions, Parenteral / Q000379:methods; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D005575:Formyltetrahydrofolates; D005467:Floxuridine; D002955:Leucovorin